Loading
Yanuki
SUBCATEGORY FEED
uniQure Secures $175M Debt Facility to Advance Huntington's Disease Therapy | Incannex Healthcare (IXHL) Sees Positive Momentum from OSA Trial and Strategic Moves | Vanda Pharmaceuticals to Participate in Mizuho Neuro & Ophthalmology Summit 2025 | uniQure Secures $175M Debt Facility to Advance Huntington's Disease Therapy | Incannex Healthcare (IXHL) Sees Positive Momentum from OSA Trial and Strategic Moves | Vanda Pharmaceuticals to Participate in Mizuho Neuro & Ophthalmology Summit 2025

Finance / Biotech

uniQure Secures $175M Debt Facility to Advance Huntington's Disease Therapy

uniQure (QURE) has secured a $175 million non-dilutive senior secured term loan facility with Hercules Capital (HTGC) to bolster its financial flexibility. This funding aims to support the potential commercial launch of AMT-130, uniQure's g...

uniQure Secures $175M Debt Facility to Advance Huntington's Disease Therapy Image via Yahoo Finance
uniQure Announces Refinancing of Existing $50 Million Debt and Securing Up to an Additional $125 Million in Non-Dilutive Funding
Stocks Stock Market Earnings Markets Crypto Cryptocurrency Investing Stock Analysis Company News Economy